Asking
Asking
Grasping
Coping

News Flash 10.2015

The FDA has expanded the approved use of Keytruda (Pembrolizumab) to also treat patients with advanced non-small cell lung cancer (NSCLC) whose disease has progressed after receiving the standard treatments. Nevertheless, these patients will first have to undergo a specific laboratory test in order to identify those who may benefit from the new therapy. In […]

News Flash 9.2015

Currently approved antiemetic drugs (i.e. drugs for the treatment of nausea and vomiting), generally target the acute phase of nausea and vomiting (i.e. nausea and vomiting that occur in the first 24 hours after the start of chemotherapy). Yet, many patients also experience delayed nausea and vomiting that occur from 24 to 120 hours or […]

News Flash 4.2015

In March 2015, the FDA granted approval for Nivolumab (Opdivo) for the treatment of patients with advanced squamous non-small cell lung cancer that has progressed after treatment with chemotherapy. Nivolumab works by enhancing the ability of the immune system to fight and destroy cancer cells (see:” Keytruda – a new anti-cancer drug”). Nivolumab is already […]

News Flash 3.2015

In February 2015, the FDA granted accelerated approval for a new drug, Palbociclib (Ibrance), for the treatment of post-menopausal women with advanced breast cancer whose tumors are hormone receptor positive and HER-2 negative.Defined as a breakthrough therapy among these patients, Palbociclib, given as tablets, signals a new strategy for arresting cell tumor growth. In a […]

Recent Cancer Data; Incidence and Mortality

According to recent data from the USA, the lifetime probability of being diagnosed with cancer is about 44% for men and about 38% for women. In other words, almost one in two men and more than one in three women will develop cancer during their lifetime. Yet, it is important to note that during the last […]

Accessibility Toolbar